Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events

Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
doi: https://doi.org/10.1101/2024.02.14.24302840

Article Information

doi 
https://doi.org/10.1101/2024.02.14.24302840
History 
  • February 15, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Tigran Makunts1,*,
  2. Siranuysh Grabska1,2,3,
  3. Hovakim Grabski1,2,3 and
  4. Ruben Abagyan1
  1. 1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 92093, United States
  2. 2Institute of Biomedicine and Pharmacy, RAU, Yerevan, 0051, Armenia
  3. 3L.A. Orbeli Institute of Physiology, National Academy of Sciences, Yerevan, 0028, Armenia
  1. ↵*Correspondence: Tigran Makunts, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 92093, United States; tmakunts{at}health.ucsd.edu
Back to top
Posted February 15, 2024.
Download PDF
Data/Code
Email
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events
Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
medRxiv 2024.02.14.24302840; doi: https://doi.org/10.1101/2024.02.14.24302840
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area